Roche
F. Hoffmann-La Roche AG, Basel, SwitzerlandGeneral Information
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and conditions and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. The Neuroscience group in Roche has expertise in many areas, including autism spectrum disorder (ASD), Alzheimer’s disease, schizophrenia, depression, and imaging which spans from discovery where Roche scientists have made major advancements in identifying pathways involved in ASD, schizophrenia and depression to the clinic where innovative new first-in-class medications are being developed for these major psychiatric disorders.
Role in AIMS-2-TRIALS
The Neuroscience group at Roche is committed to contribute to the success of AIMS-2-TRIALS. As part of the project Roche aims to bring experience in designing meaningful trials to understand meaningful endpoints for people with ASD. Through the broad collaboration we hope to be able to understand the wants and needs of the community more broadly, so that all groups can develop meaningful approaches to help people with ASD.
Christopher Chatham
Biomarker Experimental Medicine Leader
Elizabeth Ashford
Operations Program Leader
Barbara Biemans
Principal Scientist
Lindsay Ham
Regulatory Affairs Specialist
Jörg Hipp
Principal Scientist
Denise Morgan
Regulatory Affairs Specialist
Lorraine Murtagh
NDD Leader
Alma Rubio
Head of Patient Partnership
Kevin Sanders
Global Development Lead – Autism
Lisa Shafe
Clinical Programme Leader
Will Spooren
Former Project Lead (Emeritus)
Jeroen Tinbergen
Daniel Umbricht
Distinguished Scientist
Adrian Ward
International Health Policy Leader